Search

Search Constraints

You searched for: Author/Creator Cohen, Pascal

Search Results

1. 0024 Effects of chronic low-dose exposure to ionising radiation on physician micro-vascular structure revealed by nail fold capillaroscopy. (23rd June 2014)

2. 117. PREDICTION OF LONG-TERM EVOLUTIONARY PROFILES IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG– STRAUSS) BASED ON BASELINE AND FOLLOW-UP CHARACTERISTICS. (29th March 2019)

3. 354. EFFICACY OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS TREATMENTS ACCORDING TO THE TYPE OF MANIFESTATIONS BASED ON ANALYSIS OF 636 PATIENTS. (29th March 2019)

4. Adding Azathioprine to Remission‐Induction Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis (Churg‐Strauss), Microscopic Polyangiitis, or Polyarteritis Nodosa Without Poor Prognosis Factors: A Randomized, Controlled Trial. Issue 11 (15th October 2017)

5. Brief Report: Childhood‐Onset Systemic Necrotizing Vasculitides: Long‐Term Data From the French Vasculitis Study Group Registry. Issue 7 (July 2015)

6. Cardiac Intravoxel Incoherent Motion Diffusion‐Weighted Magnetic Resonance Imaging With T1 Mapping to Assess Myocardial Perfusion and Fibrosis in Systemic Sclerosis: Association With Cardiac Events From a Prospective Cohort Study. Issue 9 (2nd August 2020)

7. Comparative study of granulomatosis with polyangiitis subsets according to ANCA status: data from the French Vasculitis Study Group Registry. Issue 1 (16th March 2022)

8. Corrigendum to: Predictive factors of severe infections in patients with systemic necrotizing vasculitides: data from 733 patients enrolled in five randomized controlled trials of the French Vasculitis Study Group. (23rd January 2020)

9. Corrigendum to: Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysis. (23rd May 2020)

10. Corrigendum to: Rituximab for induction and maintenance therapy of granulomatosis with polyangiitis: a single-centre cohort study on 114 patients. (3rd March 2022)